Lite Strategy LITS
NASDAQ LITS
$1.06 +0.00 (+0.00%)
At close: Sep 10, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Invested Capital (2025 - 2026)

Lite Strategy (LITS) posted Invested Capital of $56.8 million for Q1 2026, down 30.57% on a QoQ basis from $81.9 million in Q4 2025.

Analysis

Lite Strategy (LITS) Invested Capital (2025 - 2026) Analysis & Trends

Lite Strategy has reported Invested Capital for 2 years, with the latest figure at $56.8 million in Q1 2026.

  • On a quarterly basis, Invested Capital changed N/A year-over-year to $56.8 million in Q1 2026; TTM through Mar 2026 was $56.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $16.9 million, changed N/A from the prior year.
  • Invested Capital was $56.8 million for Q1 2026 at Lite Strategy, down from $81.9 million in the prior quarter.
  • The five-year high for Invested Capital was $81.9 million in Q4 2025, with the low at $16.9 million in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 74.44 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 40.49 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 33.70 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 7.35 Bn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn -
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 26.94 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -
10 Lite Strategy 38.03 Mn 30.49 Mn - 56.85 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 56.85 Mn
Dec 31, 2025 81.88 Mn
Jun 30, 2025 16.93 Mn